Antibody-Based Immunotoxins for Colorectal Cancer Therapy

Monoclonal antibodies (mAbs) are included among the treatment options for advanced colorectal cancer (CRC). However, while these mAbs effectively target cancer cells, they may have limited clinical activity. A strategy to improve their therapeutic potential is arming them with a toxic payload. Immun...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Laura Sanz, Raquel Ibáñez-Pérez, Patricia Guerrero-Ochoa, Javier Lacadena, Alberto Anel
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	immunotoxin CRC toxins monoclonal antibody toxic payload targeting moiety Biology (General) QH301-705.5
Acceso en línea:	https://doaj.org/article/3a4561937d03438ab89cf496388960d8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3a4561937d03438ab89cf496388960d8
record_format	dspace
spelling	oai:doaj.org-article:3a4561937d03438ab89cf496388960d82021-11-25T16:51:26ZAntibody-Based Immunotoxins for Colorectal Cancer Therapy10.3390/biomedicines91117292227-9059https://doaj.org/article/3a4561937d03438ab89cf496388960d82021-11-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1729https://doaj.org/toc/2227-9059Monoclonal antibodies (mAbs) are included among the treatment options for advanced colorectal cancer (CRC). However, while these mAbs effectively target cancer cells, they may have limited clinical activity. A strategy to improve their therapeutic potential is arming them with a toxic payload. Immunotoxins (ITX) combining the cell-killing ability of a toxin with the specificity of a mAb constitute a promising strategy for CRC therapy. However, several important challenges in optimizing ITX remain, including suboptimal pharmacokinetics and especially the immunogenicity of the toxin moiety. Nonetheless, ongoing research is working to solve these limitations and expand CRC patients’ therapeutic armory. In this review, we provide a comprehensive overview of targets and toxins employed in the design of ITX for CRC and highlight a wide selection of ITX tested in CRC patients as well as preclinical candidates.Laura SanzRaquel Ibáñez-PérezPatricia Guerrero-OchoaJavier LacadenaAlberto AnelMDPI AGarticleimmunotoxinCRCtoxinsmonoclonal antibodytoxic payloadtargeting moietyBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1729, p 1729 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	immunotoxin CRC toxins monoclonal antibody toxic payload targeting moiety Biology (General) QH301-705.5
spellingShingle	immunotoxin CRC toxins monoclonal antibody toxic payload targeting moiety Biology (General) QH301-705.5 Laura Sanz Raquel Ibáñez-Pérez Patricia Guerrero-Ochoa Javier Lacadena Alberto Anel Antibody-Based Immunotoxins for Colorectal Cancer Therapy
description	Monoclonal antibodies (mAbs) are included among the treatment options for advanced colorectal cancer (CRC). However, while these mAbs effectively target cancer cells, they may have limited clinical activity. A strategy to improve their therapeutic potential is arming them with a toxic payload. Immunotoxins (ITX) combining the cell-killing ability of a toxin with the specificity of a mAb constitute a promising strategy for CRC therapy. However, several important challenges in optimizing ITX remain, including suboptimal pharmacokinetics and especially the immunogenicity of the toxin moiety. Nonetheless, ongoing research is working to solve these limitations and expand CRC patients’ therapeutic armory. In this review, we provide a comprehensive overview of targets and toxins employed in the design of ITX for CRC and highlight a wide selection of ITX tested in CRC patients as well as preclinical candidates.
format	article
author	Laura Sanz Raquel Ibáñez-Pérez Patricia Guerrero-Ochoa Javier Lacadena Alberto Anel
author_facet	Laura Sanz Raquel Ibáñez-Pérez Patricia Guerrero-Ochoa Javier Lacadena Alberto Anel
author_sort	Laura Sanz
title	Antibody-Based Immunotoxins for Colorectal Cancer Therapy
title_short	Antibody-Based Immunotoxins for Colorectal Cancer Therapy
title_full	Antibody-Based Immunotoxins for Colorectal Cancer Therapy
title_fullStr	Antibody-Based Immunotoxins for Colorectal Cancer Therapy
title_full_unstemmed	Antibody-Based Immunotoxins for Colorectal Cancer Therapy
title_sort	antibody-based immunotoxins for colorectal cancer therapy
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/3a4561937d03438ab89cf496388960d8
work_keys_str_mv	AT laurasanz antibodybasedimmunotoxinsforcolorectalcancertherapy AT raquelibanezperez antibodybasedimmunotoxinsforcolorectalcancertherapy AT patriciaguerreroochoa antibodybasedimmunotoxinsforcolorectalcancertherapy AT javierlacadena antibodybasedimmunotoxinsforcolorectalcancertherapy AT albertoanel antibodybasedimmunotoxinsforcolorectalcancertherapy
_version_	1718412888086937600

Antibody-Based Immunotoxins for Colorectal Cancer Therapy

Ejemplares similares